O2 RegenTech, a medical device startup out of the University of Akron, is working on development of OXAID, a dressing for the treatment of chronic wounds with particular focus on would care. Initially targeted to those suffering from diabetic foot ulcers, 02 RegenTech's product differs from current hydrogel wound dressings in that its patent-pending technology combines moisture, oxygen and antimicrobial properties more effectively to heal wounds. This technique, it is suggested, is more cost-effective and could allows for faster recovery than traditional chronic wound dressings. The three most important factors in wound healing are oxygen, moisture, and protection from bacteria to prevent infections. Currently, it is suggested, no wound treatments are available that offer all three components at once, requiring patients to use a combination of different bandages, dressings, ointments, and other treatments. O2 RegenTech's objective is to make wound care simpler with its proprietary product, OXAIDâ¢, a treatment that provides all three important components to promote wound healing in one easy-to-use dressing
